The antiserum was produced against synthesized peptide derived from human Interferon-gamma Receptor alpha around the phosphorylation site of Tyr457. AA range:431-480

Phospho-IFNGR1 (Y457) Polyclonal Antibody detects endogenous levels of IFNGR1 protein only when phosphorylated at Y457.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):GyDKP

IFNGR1

Interferon gamma receptor 1

IFNGR1 ;
Interferon gamma receptor 1 ;
IFN-gamma receptor 1 ;
IFN-gamma-R1 ;
CDw119 ;
CD antigen CD119

This gene (IFNGR1) encodes the ligand-binding chain (alpha) of the gamma interferon receptor. Human interferon-gamma receptor is a heterodimer of IFNGR1 and IFNGR2. A genetic variation in IFNGR1 is associated with susceptibility to Helicobacter pylori infection. In addition , defects in IFNGR1 are a cause of mendelian susceptibility to mycobacterial disease , also known as familial disseminated atypical mycobacterial infection. [provided by RefSeq , Jul 2008] ,

Disease:Defects in IFNGR1 are a cause of mendelian susceptibility to mycobacterial disease (MSMD) [MIM:209950]; also known as familial disseminated atypical mycobacterial infection. This rare condition confers predisposition to illness caused by moderately virulent mycobacterial species , such as Bacillus Calmette-Guerin (BCG) vaccine and environmental non-tuberculous mycobacteria , and by the more virulent Mycobacterium tuberculosis. Other microorganisms rarely cause severe clinical disease in individuals with susceptibility to mycobacterial infections , with the exception of Salmonella which infects less than 50% of these individuals. The pathogenic mechanism underlying MSMD is the impairment of interferon-gamma mediated immunity whose severity determines the clinical outcome. Some patients die of overwhelming mycobacterial disease with lepromatous-like lesions in early childhood , whereas others develop , later in life , disseminated but curable infections with tuberculoid granulomas. MSMD is a genetically heterogeneous disease with autosomal recessive , autosomal dominant or X-linked inheritance. ,Function:Receptor for interferon gamma. Two receptors bind one interferon gamma dimer. ,online information:IFNGR1 mutation db ,polymorphism:A genetic variation in the IFNGR1 gene is associated with susceptibility to Helicobacter pylori infection [MIM:600263]. ,PTM:Phosphorylated at Ser/Thr residues. ,similarity:Belongs to the type II cytokine receptor family. ,similarity:Contains 2 fibronectin type-III domains. ,similarity:Contains 2 Ig-like C2-type (immunoglobulin-like) domains. ,subunit:Monomer. ,

Cell membrane ; Single-pass type I membrane protein .

>>Cytokine-cytokine receptor interaction ;
>>HIF-1 signaling pathway ;
>>Necroptosis ;
>>Osteoclast differentiation ;
>>JAK-STAT signaling pathway ;
>>Natural killer cell mediated cytotoxicity ;
>>Th1 and Th2 cell differentiation ;
>>Th17 cell differentiation ;
>>Leishmaniasis ;
>>Chagas disease ;
>>Toxoplasmosis ;
>>Tuberculosis ;
>>Influenza A ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Herpes simplex virus 1 infection ;
>>Pathways in cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Inflammatory bowel disease